• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Author Archive for: "Nascent Biotech"
 Letter to Shareholders from Sean Carrick
0
By Nascent Biotech
In Corporate News
Posted April 17, 2025

Letter to Shareholders from Sean Carrick

Dear Shareholder,  The past eighteen months have been a challenging time for Nascent Biotech. After successfully completing Phase I establishing safety at multiple ascending cohorts and showing [...]

READ MORE
 Message From Senior Management
0
By Nascent Biotech
In Corporate News
Posted February 11, 2025

Message From Senior Management

601 21st Street, Suite 300 Vero Beach, FL 32960 February 11, 2025 Dear Shareholder: Our fiscal year will end March 31, 2025, and this year has proven to be challenging, yet productive.  We [...]

READ MORE
 VIDEO: Nascent Biotech CEO Sean Carrick at the Emerging Grown Conference
0
By Nascent Biotech
In Corporate News, News, Science News
Posted September 10, 2024

VIDEO: Nascent Biotech CEO Sean Carrick at the Emerging Grown Conference

READ MORE
 Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted April 16, 2024

Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run

NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted February 6, 2024

Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates

NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”), a clinical-stage biotechnology [...]

READ MORE
 Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
0
By Nascent Biotech
In Corporate News
Posted January 9, 2024

Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued

Analysts suggest Nascent Value at $0.60 to $2.84 per share NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, [...]

READ MORE
 Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
0
By Nascent Biotech
In Uncategorized
Posted December 19, 2023

Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk

NORTH PALM BEACH, FL / ACCESSWIRE / December 19, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Marble Arch Research: What is Pritumumab and How it Works
0
By Nascent Biotech
In Corporate News, News
Posted December 6, 2023

Marble Arch Research: What is Pritumumab and How it Works

CLICK HERE TO DOWNLOAD COMPLETE PDF

READ MORE
 2023 ASCO Annual Meeting: Phase 1 Study of Pritumumab in Brain Cancer
0
By Nascent Biotech
In News, Science News
Posted December 6, 2023

2023 ASCO Annual Meeting: Phase 1 Study of Pritumumab in Brain Cancer

CLICK TO DOWNLOAD PDF

READ MORE
 Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
0
By Nascent Biotech
In Science News
Posted August 22, 2023

Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer

NORTH PALM BEACH, FL / ACCESSWIRE / August 22, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
1 2 3 4 5 6 7 8 9 ...
page 1 of 11
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.